Deeper MRD response associated with better survival in obe-cel-treated patients with B-cell ALL Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in patients with B-cel...

Deeper MRD response associated with better survival in obe-cel-treated patients with B-cell #ALL #Tandem2025

sohoinsider.com/meeting-news...

Study questions clinical benefit of dexamethasone with axi-cel in LBCL patients Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a study presented at the 2025 Transpo...

Study questions clinical benefit of dexamethasone with axi-cel in #LBCL patients
#Tandem25 #Tandem2025

sohoinsider.com/meetings-con...

ACROBAT interim results support AlloHeme for relapse prediction in #AML, #MDS #tandem2025

sohoinsider.com/meetings-con...

#Tandem2025 #ASTCT

At #Tandem2025 talking about public funding for cancer research and the CIBMTR Biorepository. Missing my NIH friends due to the ban.

Andy Sharenberg #UmojaBio presents the direct in vivo platform to create CAR-T #Tandem2025

Here we go! Day 1 #Tandem2025 #Hawaii @mskcancercenter.bsky.social @cibmtr.bsky.social @astct.bsky.social

Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma Patients Roswell Park experts will share new discoveries and insights at the 2025 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and...

Exciting breakthroughs in cell therapy and stem cell transplant are being unveiled at #Tandem2025! 🧬✨

Learn more about these important developments and other key research: www.roswellpark.org/newsroom/202...